The American Association for Cancer Research Congratulates Margaret Hamburg, M.D., on her Nomination as Commissioner of the Food and Drug Administration
March 16, 2009
PHILADELPHIA - The American Association for Cancer Research (AACR) extends its sincere congratulations to Margaret Hamburg, M.D., on her nomination to lead the U.S. Food and Drug Administration (FDA).
As FDA commissioner, Hamburg will oversee the advancement of cutting-edge products and therapies that are central to the treatment and prevention of cancer. Her leadership will bring new perspectives to important FDA initiatives, such as devising regulatory pathways for biomarker approval and the co-development of therapies and tests, as well as efforts to develop the next generation of clinical trials.
The AACR is confident that she will provide the expertise, integrity and leadership needed to revitalize the agency's scientific foundation for the benefit of millions of cancer patients who depend on the agency to ensure the safety and efficacy of new therapies and products.
Hamburg's distinguished career as a physician-scientist and experience in state and federal government as assistant secretary for planning and evaluation at the U.S. Department of Health and Human Services, as New York City health commissioner, and her current position as senior scientist for the Global Health and Security Initiative, make her an ideal candidate to provide the FDA with a fresh vision for the future.
As the authoritative source of information about advances in the causes, diagnosis, treatment and prevention of cancer, the AACR looks forward to working with Hamburg and serving as a resource to ensure the FDA maintains its prominence at the forefront of innovation and cutting-edge regulatory science.
# # #
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and 80 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. The AACR's most recent publication and its sixth major journal, Cancer Prevention Research, is dedicated exclusively to cancer prevention, from preclinical research to clinical trials. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.